Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

@article{Mulligan2020PhaseIS,
  title={Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults},
  author={M. Mulligan and K. Lyke and N. Kitchin and J. Absalon and A. Gurtman and S. Lockhart and K. Neuzil and V. Raabe and R. Bailey and K. Swanson and Ping Li and K. Koury and W. Kalina and D. Cooper and C. Fontes-Garfias and P. Shi and {\"O}. T{\"u}reci and Kristin R Tompkins and E. Walsh and R. Frenck and A. Falsey and P. Dormitzer and W. Gruber and U. Şahin and K. Jansen},
  journal={Nature},
  year={2020},
  pages={1-5}
}
In March 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 , a pandemic. With rapidly accumulating numbers of cases and deaths reported globally 2 , a vaccine is urgently needed. Here we report the available safety, tolerability and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose-escalation study (ClinicalTrials.gov identifier NCT04368728) among… Expand
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
TLDR
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults support the selection of BNT162b2 for advancement to a pivotal phase 2–3 safety and efficacy evaluation. Expand
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
TLDR
Vaccination with BNT162b2 at well tolerated doses elicits a combined adaptive humoral and cellular immune response, which together may contribute to protection against COVID-19. Expand
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
TLDR
The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms. Expand
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
TLDR
The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate, and systemic adverse events were less common in cohort 3 than in cohort 1 and in those who received the low vaccine dose than in thoseWho received the high dose, while reactogenicity was lower after the second dose. Expand
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
TLDR
At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum, and the addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response. Expand
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
TLDR
Preliminary safety, tolerability and immunogenicity data from an ongoing single-center, parallel-group, double-blind phase 1 trial of the vaccine candidate BNT162b1 in 144 healthy SARS-CoV-2-naive Chinese participants suggest it has an acceptable safety profile and produces high levels of humoral and T cell responses in an Asian population. Expand
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial
TLDR
The most frequent local adverse event (AE) was injection site pain and the most frequent solicited AEs were fatigue, headache and myalgia, indicative of a Th1-skewed phenotype in both cohorts. Expand
Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
Background Vaccination is one of the most important tools to control the COVID-19 pandemic. However, there is little information on the antibody response inExpand
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
TLDR
Exploratory analyses of the immune responses in adults, aged 18-55 years, up to 8 weeks after vaccination with a single dose of ChAdOx1 nCoV-19 suggest a favorable immune profile induced by this vaccine candidate, supporting the progression of this vaccines candidate to ongoing phase 2/3 trials to assess vaccine efficacy. Expand
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
TLDR
Vaccination with mRNA-1273 resulted in significant immune responses to SARS-CoV-2 in participants 18 years and older, with an acceptable safety profile, confirming the safety and immunogenicity of 50 and 100 ug mRNA- 1273 given as a 2 dose-regimen. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
TLDR
Additional safety and immunogenicity data from the US Phase 1 trial supported selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway. Expand
Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine
TLDR
The robust RBD-specific antibody, T-cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest multiple beneficial mechanisms with potential to protect against COVID-19. Expand
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
TLDR
It is shown that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell, and monoclonal antibodies isolated here are promising candidates for COVID-19 treatment and prevention. Expand
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine
TLDR
This Ebola vaccine candidate elicited anti‐Ebola antibody responses and these results support further evaluation of the vaccine dose of 20 million PFU for preexposure prophylaxis and suggest that a second dose may boost antibody responses. Expand
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
TLDR
The first mRNA vaccines against H10N8 and H7N9 influenza viruses were well tolerated and elicited robust humoral immune responses and reactogenicity profiles. Expand
An Infectious cDNA Clone of SARS-CoV-2
TLDR
The reverse genetic system and reporter virus provide key reagents to study SARS-CoV-2 and develop countermeasures and were successfully used to evaluate the antiviral activities of interferon (IFN). Expand
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
TLDR
This first-ever demonstration in human beings shows that a prophylactic mRNA-based candidate vaccine can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needles-syringe. Expand
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
TLDR
A fluorescence-based SARS-CoV-2 neutralization assay is reported on that detects Sars- CoV- 2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. Expand
Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020
TLDR
The COVID-19 pandemic continues to be severe, particularly in certain population groups, and the need to build on current efforts to collect and analyze case data, especially among those with underlying health conditions is underscored. Expand
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
TLDR
A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19, and demonstrates the speed and robustness of advanced antibody discovery platforms. Expand
...
1
2
3
...